Ceritinib (LDK378)

Price	USD1.00
Packge	1KG

Product Details

Product NameCeritinib (LDK378)
CAS No.1032900-25-6
EINECS No.811-457-8
MFC28H36ClN5O3S
MW558.14
AppearanceOff-white solid.White to Off-White
Boiling point 720.7±70.0 °C(Predicted)
density 1.251±0.06 g/cm3(Predicted)
storage temp. -20°C Freezer
Melting point 173-175°C

JD607

Product Name:	Ceritinib (LDK378)
Synonyms:	LDK378;5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine;5-chloro-N2-(2-isopropoxy-5-Methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyriMidine-2,4-diaMine;LDK378/LDK-378;5-Chloro-N4-[2-[(1-Methylethyl)sulfonyl]phenyl]-N2-[5-Methyl-2-(1-Methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyriMidinediaMine;ceritinib;LDK378 Ceritinib;Ceritinib (LDK378)
CAS:	1032900-25-6
MF:	C28H36ClN5O3S
MW:	558.13514
EINECS:	-0
Product Categories:	API;Inhibitors
Mol File:	1032900-25-6.mol

Ceritinib (LDK378) Chemical Properties

Safety Information

MSDS Information

Ceritinib (LDK378) Usage And Synthesis

Indications and Usage	Ceritinib is a new ALK gene inhibitor (ALKi) developed by Novartis Pharmaceuticals; its commercial name is Zykadia, and its previous code was LDK378. It was approved by the FDA for sale on April 29, 2014, and it is used to treat anaplastic lymphoma kinase (ALK) positive transfer of crizotinib (CRZ) progress or intolerance of non-small cell lung cancer (NSCLC).
Mechanisms of Action	Crizotinib resistance is a major issue for patients undergoing treatment for ALK gene rearrangement positive non-small cell lung cancer. Ceritinib is a kind of ALK tyrosine kinase inhibitor. Ceritinib does not target the MET proto-oncogene, but instead inhibits the insulin-like growth factor 1 receptor and blocks proteins from promoting cancer cell development, thus inhibiting the expression of EML4-ALK and NPM-ALK fusion protein cells. It is used to treat ALK rearrangement positive NSCLC patients who have previously used Crizotinib and can overcome Crizotinib resistance. Compared to Crizotinib, Ceritinib does not inhibit MET kinase activity, but inhibits IGF-1 receptors. Whether in terms of enzyme reaction, cell analysis or Crizotinib resistant animal models, research results all show that Ceritinib is more effective than Crizotinib. Additionally, regardless of any ALK resistance mutation, Ceritinib is still highly effective. In clinical models, Ceritinib’s ALK inhibition has 20 times the tumor-fighting effect of Crizotinib. Ceritinib also has the same effect on Crizotinib resistant central nervous system lesion NSCLC. Clinical trials show that Ceritinib can effectively inhibit ALK targets, potentially affecting an unknown kinase related to drug resistance, thus overcoming Crizotinib resistance.
Patents	American patent numbers: US7153964，US7893074，US7964592，US8039474，US8039479，US8377921，US8703787. Patent expiration dates: February 26, 2021 (US7153964) April 25, 2026 (US7893074) January 13, 2027 (US7964592) June 29, 2030 (US8039474, US8039479) November 20, 2027 (US8377921) April 29, 2032 (US8703787) Patents belong to Novartis
Definition	ChEBI: A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.

Company Profile Introduction

Henan CoreyChem Co., Ltd, based on the original Zhengzhou Cote Chemical Research Institute, be brave in absorbing highly educated talents & overseas returnees; actively responded to Zhengzhou City High-tech Zone Government’s Special Care Policy, reorganized and founded in National University of Science and Technology Park, which is a high-tech, stock enterprise of high-end chemical Custom synthesis;The park was created by the People's Government of Henan Province, and proved by Ministry of Education and the National Science & Technology, taking the construction mode of "many college a park, and common development", mainly depends on Zhengzhou University and Henan University’s scientific research and talent advantage to set up Universities, scientific research institute and enterprise scientific research achievements transformation platform, to make high-tech enterprises incubate, is the new high-tech talent gathering base, high and new technology industry enterprise radiation base, colleges and universities technological innovation base.

Henan Coreychem Co., Ltd, facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.

Recommended supplier

VIP1年
SETV ASRV LLP
CERITINIB 95-99%
Inquiry
2024-09-11

VIP1年
Varanous Labs Pvt Ltd
1032900-25-6 98%
Inquiry
2023-12-26

Product Details

Company Profile Introduction

Recommended supplier

career henan chemical co